The stock of Concordia International Corp (NASDAQ:CXRX) reached all time low today, Nov, 7 and still has $1.76 target or 14.00% below today’s $2.05 share price. This indicates more downside for the $162.74M company. This technical setup was reported by Barchart.com. If the $1.76 PT is reached, the company will be worth $22.78M less.
Trading stocks at an all time low is not easy. Stock at an all time low usually experience even more downside due to very negative fundament. Even thought the pullback rate is high, shorting is not an easy job because the risk of being wrong is big and the risk-reward ratio is always worse than if trading lon only. About 6.09 million shares traded hands or 167.11% up from the average. Concordia International Corp (NASDAQ:CXRX) has declined 87.26% since April 5, 2016 and is downtrending. It has underperformed by 89.22% the S&P500.
Analysts await Concordia International Corp (NASDAQ:CXRX) to report earnings on November, 10. They expect $1.35 earnings per share, up 3.05% or $0.04 from last year’s $1.31 per share. CXRX’s profit will be $107.70 million for 0.38 P/E if the $1.35 EPS becomes a reality. After $1.21 actual earnings per share reported by Concordia International Corp for the previous quarter, Wall Street now forecasts 11.57% EPS growth.
Concordia International Corp (NASDAQ:CXRX) Ratings Coverage
Out of 9 analysts covering Concordia Healthcare Corp. (NASDAQ:CXRX), 5 rate it a “Buy”, 0 “Sell”, while 4 “Hold”. This means 56% are positive. Concordia Healthcare Corp. has been the topic of 18 analyst reports since August 11, 2015 according to StockzIntelligence Inc. The firm earned “Hold” rating on Monday, August 15 by GMP Securities. The rating was maintained by Canaccord Genuity with “Buy” on Tuesday, August 11. The stock has “Hold” rating given by TD Securities on Thursday, August 4. Laurentian maintained Concordia International Corp (NASDAQ:CXRX) on Tuesday, March 29 with “Buy” rating. As per Monday, October 19, the company rating was upgraded by Mackie. The stock of Concordia International Corp (NASDAQ:CXRX) has “Underperformer” rating given on Monday, August 15 by IBC. The stock has “Sector Perform” rating given by Scotia Capital on Monday, September 19. The firm has “Sector Outperform” rating by Scotia Capital given on Tuesday, September 29. The stock of Concordia International Corp (NASDAQ:CXRX) has “Outperform” rating given on Thursday, October 1 by RBC Capital Markets. Scotia Capital maintained the shares of CXRX in a report on Friday, October 16 with “Sector Outperform” rating.
According to Zacks Investment Research, “Concordia International Corp is a diverse pharmaceutical company which focused on legacy pharmaceutical products and orphan drugs. The company also markets orphan drugs through its Orphan Drug Division, currently consisting of Photofrin(R) for the treatment of certain rare forms of cancer, which is currently undergoing testing for potential new indications. Concordia International Corp, formerly known as Concordia Healthcare Corp, is headquartered in Oakville, Canada.”
More notable recent Concordia International Corp (NASDAQ:CXRX) news were published by: Prnewswire.com which released: “Concordia International Corp. Announces Communication With CMA” on October 25, 2016, also Finance.Yahoo.com with their article: “Concordia International Corp. Announces CEO Transition Plan” published on October 21, 2016, Marketwatch.com published: “Concordia International Corp. Announces Second Cross Currency Swap Agreement” on November 01, 2016. More interesting news about Concordia International Corp (NASDAQ:CXRX) were released by: Prnewswire.com and their article: “Shareholder Class Action Filed Against Concordia International Corp. – CXRX” published on August 17, 2016 as well as Business.Financialpost.com‘s news article titled: “Concordia International Corp takeover unlikely â€“ Goldman” with publication date: September 27, 2016.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.